A study on a handful of people with suspected mild Alzheimer's disease (AD) suggests that a device that sends continuous electrical impulses to specific "memory" regions of the brain appears to increase neuronal activity. Results of the study using deep brain stimulation, a therapy already used in some patients with ...

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of ...

(Johns Hopkins Medical Institutions) A study on a handful of people with suspected mild Alzheimer's disease (AD) suggests that a device that sends continuous electrical impulses to specific "memory" regions of the brain appears to increase neuronal activity. Results of the study using deep brain stimulation, a therapy already used ...

A drug prescribed for Alzheimer's disease does not ease clinically significant agitation in patients, according to a new study conducted by researchers from the U.K., U.S. and Norway. This is the first randomized controlled trial designed to assess the effectiveness of the drug (generic name memantine) for significant agitation in ...

Alzheimer's disease (AD) is a major neurodegenerative disorder that affects millions of people worldwide. New and accurate techniques for early diagnosis are critical. Pravat K. Mandal, PhD, and his colleagues have developed a completely non-invasive brain imaging technique to measure specific brain chemical changes. This provides a signature of the ...

Mount Sinai School of Medicine researchers have succeeded in developing a biosynthetic polyphenol that improves cognitive function in mice with Alzheimer's disease (AD). The findings, published in a recent issue of the Journal of Neuroscience, provide insight in determining the feasibility of biosynthetic polyphenols as a possible therapy for AD ...

Current research does not support the use of smell tests for predicting Alzheimer's dementia, according to a comprehensive review by Robert Wood Johnson Foundation Clinical Scholars at the University of Michigan and the VA Center for Clinical Management Research.

A highly toxic beta-amyloid - a protein that exists in the brains of Alzheimer's disease victims - has been found to greatly increase the toxicity of other more common and less toxic beta-amyloids, serving as a possible "trigger" for the advent and development of Alzheimer's, researchers at the University of ...

By Alan Mozes HealthDay Reporter WEDNESDAY, May 2 (HealthDay News) -- Consuming foods rich in omega-3 fatty acids may guard against Alzheimer's disease, new research suggests. The finding stems from work conducted among roughly 1,200 dementia-free patients over the age of 65. ...

Researchers at Mount Sinai School of Medicine have gained insight into the mechanism by which a pathological brain protein called tau contributes to the progression of Alzheimer's disease (AD) and other neurodegenerative disorders. This finding, published in the most recent issue of the Journal of Biological Chemistry, may provide the ...

A study published online in The Laryngoscope reveals that current studies do not support the use of olfactory identification tests (smell tests) for predicting Alzheimer's dementia. Alzheimer's is a progressive disease that causes loss of brain function and is the most common cause of dementia. The disease is expected to ...

Mount Sinai School of Medicine researchers have succeeded in developing a biosynthetic polyphenol that improves cognitive function in mice with Alzheimer's disease (AD). The findings, published in a recent issue of the Journal of Neuroscience , provide insight in determining the feasibility of biosynthetic polyphenols as a possible therapy ...